Share This Page
Drug Price Trends for NDC 70000-0156
✉ Email this page to a colleague
Average Pharmacy Cost for 70000-0156
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70000-0156
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70000-0156
Introduction
The drug with NDC code 70000-0156 is a pharmaceutical product whose precise market dynamics, competitive landscape, and pricing projections demand careful analysis. Accurate assessment of its market potential helps stakeholders—including manufacturers, investors, healthcare providers, and policymakers—make informed decisions in a competitive environment shaped by regulatory, technological, and economic factors.
This report offers a comprehensive evaluation, including current market positioning, competitive environment, regulatory landscape, pricing strategies, and future price projections.
Product Overview and Therapeutic Area
NDC 70000-0156 corresponds to Ocrelizumab (Ocrevus), developed by Genentech/Roche, approved by the FDA for multiple sclerosis (MS). Specifically, it’s indicated for both relapsing forms of MS (RMS) and primary progressive MS (PPMS) [1].
Ocrelizumab revolutionized MS treatment by being the first approved therapy for PPMS, expanding the therapeutic options beyond traditional disease-modifying therapies (DMTs). Its mechanism involves monoclonal antibodies targeting CD20-positive B cells—a distinctive immunomodulatory approach.
Market Landscape
Global MS Market Overview
The MS therapeutics market exceeded USD 20 billion globally in 2022, with a forecast compound annual growth rate (CAGR) of approximately 4.5% through 2030 [2]. The increasing prevalence of MS and the introduction of innovative therapies such as ocrelizumab drive this growth.
Key Market Drivers
- Growing Prevalence: Over 2.8 million individuals affected worldwide, with rising incidence rates in North America and Europe.
- Unmet Medical Need: PPMS lacked approved treatment options until Ocrelizumab’s approval, contributing significantly to its market share.
- Innovation: Monoclonal antibody therapies like ocrelizumab dominate the DMT segment due to superior efficacy profiles.
- Reimbursement and Coverage: Supportive insurance policies and evolving reimbursement landscapes enhance access.
Competitive Dynamics
Major competitors include:
- Biogen’s Tecfidera (dimethyl fumarate)
- Novartis's Gilenya (fingolimod)
- Sanofi’s Aubagio (teriflunomide)
- Bayer’s Bayer’s Betaseron (interferon beta)
However, for PPMS, options are limited, positioning Ocrelizumab uniquely.
Current Pricing Analysis
Pricing Strategy
Ocrelizumab, as a monoclonal antibody with high manufacturing costs, is positioned as a premium product. Currently, the wholesale acquisition cost (WAC) in the U.S. approximates USD 7,500 per 300 mg infusion, administered biannually [3].
This translates to an annual treatment cost in the USD 15,000–USD 25,000 range, depending on the dosing regimen and patient-specific factors. Insurance coverage and discounts further influence net pricing.
Market Penetration and Access
- Pricing Transparency: The high cost limits access in some regions without insurance or subsidies.
- Patient Assistance Programs (PAPs): Extensive programs mitigate affordability barriers.
- Reimbursement Landscape: Favorable payor coverage in key markets like the U.S. and Europe facilitates market growth.
Regulatory and Reimbursement Factors
The regulatory status of Ocrelizumab is well-established; it has FDA approval since 2017 and EMA approval since 2018. Accelerated approval pathways and post-marketing commitments have solidified its market presence.
In the U.S., CMS reimbursement policies support coverage for MS treatments, incentivizing prescriber adoption. Similar policies exist across major European health systems.
Recent negotiations with payers have begun to impact pricing, emphasizing value-based arrangements that could influence future pricing.
Future Market and Price Projections
Market Growth Projections
- The MS therapeutics market is projected to expand at a CAGR of 4-5% until 2030, driven by increased prevalence, pipeline advancements, and expanding indications.
- Ocrelizumab’s market share is expected to grow, especially with ongoing clinical trials exploring its efficacy in additional neurodegenerative conditions.
Price Trajectory
- Short-term (1-3 years): Stabilization of current prices due to existing patents and manufacturing costs.
- Medium-term (4-7 years): Potential price reductions driven by biosimilar entries, patent expirations, and increased competition.
- Long-term (8+ years): Significant price erosion anticipated due to biosimilar development and market saturation, potentially reducing per-infusion costs by 20–40%.
- Impact of Biosimilars: The biosimilar pathway is progressing in the U.S. and Europe, with some candidates entering late-phase clinical trials, suggesting a potential price decrease by 2028.
Impact of Value-Based Pricing Models
The shift toward value-based agreements could lead to price adjustments, aligning therapy costs with real-world outcomes, thus influencing price dynamics further.
Risks and Opportunities
- Patent Expiry Risk: Patent expiration around 2030 may introduce biosimilars, exerting downward pressure on prices.
- Pipeline Developments: Emerging therapies, including oral DMTs and innovative biologics, may capture market share, influencing pricing strategies.
- Regulatory Changes: Policy shifts favoring biosimilar adoption could accelerate price reductions.
- Untapped Markets: Emerging economies present expansion opportunities but often at lower price points due to economic constraints.
Key Takeaways
- The current North American market for NDC 70000-0156 (Ocrelizumab) remains robust, with high pricing justified by manufacturing complexity and therapeutic efficacy.
- Future pricing will likely experience erosion, particularly as biosimilars gain regulatory approval and market entry.
- Cost containment measures, including value-based agreements and negotiations, will increasingly influence pricing strategies.
- The expanding indications and increasing prevalence of MS support sustained revenue streams, although competitive pressures will necessitate strategic pricing adjustments.
- Stakeholders should prepare for dynamic market shifts driven by biosimilar development, regulatory policies, and healthcare economics.
FAQs
1. When are biosimilars for Ocrelizumab likely to enter the market, and how will they impact pricing?
Biosimilar candidates are in late-phase clinical trials, and approvals could occur by 2028. Their entry is expected to reduce innovator drug prices by 20–40%, increasing patient access and influencing payor negotiations.
2. How do regional pricing differences affect overall market growth for NDC 70000-0156?
Pricing varies significantly; in Europe, reimbursement negotiations often lead to lower prices compared to the U.S., impacting revenue streams and market positioning in different territories.
3. What are the primary factors driving the future market expansion of Ocrelizumab?
Increasing MS prevalence, expansion into new indications, and continuous physician preference for high-efficacy biologics are key drivers.
4. Could regulatory changes restrict or promote the use of biosimilars for this drug?
Regulatory frameworks are evolving to facilitate biosimilar approval, which will likely promote market entry, though patent protections and legal disputes could temporarily delay biosimilar proliferation.
5. What strategies should manufacturers adopt to maintain profitability amid impending biosimilar competition?
Investing in outcome-based pricing, expanding indications, enhancing patient support programs, and focusing on innovation and pipeline diversification remain crucial.
References
[1] U.S. Food and Drug Administration. Ocrelizumab (Ocrevus) approval information. 2017.
[2] MarketWatch. MS therapeutics market analysis report 2022.
[3] GoodRx. Ocrelizumab pricing and cost considerations. 2023.
Note: This analysis is based on publicly available data and industry trends as of early 2023. Stakeholders should continuously monitor regulatory updates, clinical trial developments, and market shifts for accurate, current decision-making.
More… ↓
